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a hospital performing 50 knee and 50 hip surgeries every year, this potential for cost-
offsets would be of (-R$108,850). This would vary a lot for the perspective of HMOs 
and hospitals of different sizes, as well as depending on the costs of each decision 
maker, demanding constant customization of parameters. CONCLUSIONS: The use 
of IEI makes the pharmacoeconomic studies results more intelligible to decision 
makers, permitting them to foresee their actual application on a real practice, in dif-
ferent scenarios.
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LINKAGE OF ADMINISTRATIVE AND MEDICAL RECORDS DATABASES 
FOR INVESTIGATING PHARMACEUTICAL USE AND OUTCOMES
Huse DM1, Bizier R1, Tomic K2
1Thomson Reuters, Cambridge, MA, USA; 2Thomson Reuters, Washington, DC, USA
BACKGROUND: Use of electronic health care databases to examine pharmaceutical 
use and effects faces limitations inherent in the source of data. Medical records docu-
ment prescribing but not consumption of medication; administrative databases docu-
ment dispensing but not the original intent of the prescriber. OBJECTIVES: To 
evaluate a patient-level linked database of electronic medical records (EMR) and 
administrative claim for use in measuring both prescribing and dispensing of pharma-
ceuticals. METHODS: Claims data from Thomson Reuters MarketScan database were 
linked to the GE Centricity EMR database using probabilistic methods to overcome 
the de-identiﬁ cation required of both databases under US privacy laws. Patient-level 
records were matched based on demographic characteristics and calendar dates of 
physician visits. Multiple visits were required to reduce the likelihood of mismatches. 
The agreement between prescribing records in the EMR and claims for dispensing of 
medication was explored in the context of self-administered medication for osteopo-
rosis, including bisphosphonates and raloxifene. RESULTS: Using data from 2004–
2009, 219,529 patients were matched between the two data sources. Mean age was 
43 years and 57% were female. We identiﬁ ed 2,331 patients whose medical record 
showed new prescriptions for bisphosphonates or raloxifene (no evidence of use in 
the prior 180 days). Pharmacy claims indicated these prescriptions were ﬁ lled by 56% 
of patients within 7 days, 75% within 30 days, and 86% within 90 days. CONCLU-
SIONS: It is to be expected that there will be some degree of noncompliance, hence 
incomplete ﬁ lling of prescriptions, as observed. The lag from dispensing to prescribing 
among many patients is also consistent with use of samples for initial prescriptions. 
Overall, the example of osteoporosis therapy shows consistency between prescribing 
in EMR data and dispensing in claims data among a sample of probabilistically linked 
patient records.
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OBJECTIVES: Controlling for disease severity in observational studies is crucial to 
get an estimate with no selection bias. However, outcomes research studies using 
claims data, contain no information about disease severity. Therefore, comorbid scores 
are used for a proxy for the disease severity. There exists no severity score speciﬁ c for 
rheumatoid arthritis (RA). The goal of this study was to develop a severity index for 
rheumatoid arthritis (SIFRA) for private health care claims data. METHODS: We 
extracted the following variables related to rheumatoid arthritis from the claims data: 
total number of synthetic disease-modifying anti-rheumatic drugs (DMARDs), total 
number of biological DMARDs, tests for C-reactive protein (CRP) and erythrocyte 
sedimentation rate (ESR) ordered, rehabilitation visits, rheumatology visits, Felty’s 
syndrome and Sjogren’s syndrome, pulmonary, soft tissue nodules, joint surgery, 
number of platelet counts and chemical panels ordered, and rheumatoid factors 
testing. a linear regression model was used to create the severity score. The severity 
score was compared with the rheumatoid arthritis medical records-based index of 
severity (RARBIS) and currently-used comorbidity scores to proxy severity in out-
comes research studies related with rheumatoid arthritis. RESULTS: According to the 
Akaike Information Criterion (AIC), Bayesian Information Criterion (BIC), log likeli-
hood function, R-squared values and average squared prediction error, SIFRA per-
formed better than RARBIS, Charlson Comorbidity Score (CCI), Elixhauser 
comorbidity score and Chronic disease score. Spearman correlation with RARBIS was 
0.65 and signiﬁ cant. However, the correlation with the Charlson Comorbidity Index 
(0.1, p = 0.6521), Elixhauser Index (0.15, p = 0.5312) and Chronic disease score (0.13, 
p = 0.6011) were low and insigniﬁ cant. CONCLUSIONS: Comorbidity scores (Charl-
son, Elixhauser or Chronic Disease Scores) commonly used in outcomes research are 
inadequate to be proxy variable for RA patients. SIFRA, at least for rheumatoid 
arthritis, controls for disease severity better than any other commonly used measure.
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OBJECTIVES: Reimbursement agencies like the United Kingdom (UK) National Insti-
tute for health and Clinical Excellence (NICE) use mathematical modelling to analyze 
the costs and beneﬁ ts of health care technologies. The structure of these models is not 
pre-speciﬁ ed, but dependent on the requirements of the decision problem on hand. 
Various decision-analytic models have been developed to assess the potential clinical 
and economic beneﬁ ts of several RA treatment regimes, including anti-TNF agents 
and early use of disease-modifying anti-rheumatic drugs (DMARDs). The main objec-
tive is to provide a guide on how to model treatment options for early rheumatoid 
arthritis, in particular etanercept. Thus, it sought to address the methodological issues 
relating to the choice of modeling technique. RESULTS: Previous analyses have used 
a variety of modelling approaches to model treatment options for RA. The rationale 
for the choice of model structure is rarely discussed in published studies and can affect 
the results produced. Advances in the treatment of RA make it necessary to develop 
a model which is ﬂ exible enough to account for different attributes (e.g. clinical remis-
sion, radiographic non-progression, and functional status), but does not increase the 
complexity of the model to an amount where it becomes too difﬁ cult to populate it 
with relevant data. Individual level models offer a solution to this problem by simulat-
ing the progression of each individual with different characteristics, where non-
Markovian distributions allow greater ﬂ exibility in modelling the timing of events. 
Further, based on the characteristics of the disease, the model should assume indepen-
dence between individuals, whilst, based on its treatment options, as assessment of 
adequate treatment response is important, time should be modeled. CONCLUSIONS: 
This work suggests that future analyses should use individual sampling models (e.g. 
simulated patient-level Markov models) for modelling the costs and beneﬁ ts of treat-
ments for RA.
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OBJECTIVES: Mapping from disease-speciﬁ c to utility measures is a research area 
gaining increasing attention. However, few studies have assessed the longitudinal 
validity of mapping models and none, to our knowledge, have compared models 
derived from baseline and post-intervention patient data. This study examined models 
derived from time-differing patient data, for mapping the Modiﬁ ed Health Assessment 
Questionnaire (MHAQ) on to the EQ-5D. METHODS: A total of 120 rheumatoid 
arthritis patients (60.0% female, mean age 59.0) completed the MHAQ and EQ-5D 
at baseline, and 3, 6 and 12 months after administration of an anti-TNFa or another 
biological agent. OLS regression produced mapping equations from baseline and post-
intervention data. Model predictive ability and explanatory power were assessed by 
root mean square error (RMSE) and adjusted R2 respectively. Pearson’s r and intra-
class correlation coefﬁ cient (ICC) assessed association and level of agreement between 
predicted and reported utilities. RESULTS: R2 (baseline, 3, 6 and to 12 months) was 
0.452, 0.418, 0.541 and 0.413 respectively, whereas prediction errors were 13.0%, 
11.1%, 8.1% and 7.2%. All equations produced a range of scores comparable to 
those achieved by the standard EQ-5D scoring algorithm, as well as strong correlations 
and agreement between reported and predicted utilities. The baseline and 12-month 
models appeared to under- and overestimate EQ-5D scores respectively, whereas the 
6-month model generated the smallest differences, typically less than the minimally 
important difference for the EQ-5D (0.03). CONCLUSIONS: Baseline data, which 
typically corresponds to lower patient HRQOL, may give mapping equations with 
compromised predictive ability, compared to models generated from post-intervention 
data, and this study showed that this factor is worth examining when longitudinal 
data are available. The next step in this line of research is to test QALY estimates and 
cost-utility increments derived from baseline and post-intervention mapping 
algorithms.
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BACKGROUND: An important consequence of rheumatoid arthritis (RA) is disabil-
ity, traditionally assessed by the Health Assessment Questionnaire (HAQ), which 
captures the physical component. Disability can also be evaluated by restricted per-
formance of social roles and those predictors haven’t been extensively studied. OBJEC-
TIVES: Determinants of social roles, among RA patients, as evaluated by paid work 
and social functioning were studied. METHODS: A total of 1,140 RA patients from 
the NDB-Portugal longitudinal cohort were analyzed. Univariate (UV) and Multivari-
ate (MV) generalized estimating equations were used to assess whether the following 
factors were determinants of paid work (1 = yes 0 = no, OR; 95%CI) and of SF-36 
social functioning (0–100, 100 is best, β; 95%CI): age, sex, marital status, educational 
level, number of people living in patient’s household, dependence on others, RA dura-
tion, number of major comorbidities, TNF, anxiolytic and/or antidepressant use, 
HAQ, disease activity (RADAI), quality of life (VASQOL), pain, fatigue and sleep 
disturbances (VAS scales, 0–10, 10 is worst). RESULTS: In MV analysis the odds of 
having a form of paid work increased with higher education (1.17; 1.12, 1.22) and 
better VASQOL (1.92; 1.15, 3.20) and decreased with higher age (0.91; 0.90, 0.93), 
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longer disease duration (0.96; 0.94, 0.98) and worse HAQ (0.74; 0.60, 0.92). Social 
functioning improved with better VASQOL (8.62; 3.32, 13.91), but worsened with 
more comorbidities (−0.92; −1.49, −0.35), anxiolytic and/or antidepressant use (−5.33; 
−7.68, −2.98), worse RADAI (−1.54; −2.80, −0.28), HAQ (−8.38; −10.51, −6.25) and 
fatigue (−1.06; −1.48, −0.65). Furthermore, the mechanism by which RADAI affected 
social functioning did not appear to be through pain (0.20; −0.43, 0.84), but through 
HAQ as it absorbed 56% of the explanatory power of RADAI. CONCLUSIONS: 
Performance of social roles was limited among RA patients with more HAQ disability, 
and improved by better quality of life. Disease activity appeared to inﬂ uence social 
functioning through worse physical disability but not through pain.
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BACKGROUND: Disease activity and disability should be assesssed at each rheuma-
toid arthritis (RA) patient visit to monitor response to therapy. Disease activity has 
been traditionally evaluated by the disease activity scale (DAS-28) and the ACR cri-
teria, which depend on physicians, but few studies have analyzed short-term predictors 
of the patient self-reported RA disease activity index-RADAI. Disability is routinely 
assessed by the health assessment questionnaire (HAQ) whose long term predictors, 
but not short-term, have been extensively studied. OBJECTIVES: To analyze whether 
the 6-month baseline levels of HAQ and of RADAI and other factors predict change 
at 6-month intervals. METHODS: RA patients from the biannual NDB-Portugal 
cohort were used. For each patient, differences between two consecutive 6-month 
intervals were computed for HAQ (0–3, 3 is worse) and RADAI (0–10, 10 is worse). 
For each scale, a binary outcome was constructed based upon these differences, where 
a positive increment meant worsening in function and disease activity. Patients’ obser-
vations whose increments were null were excluded. Univariate (UV) and multivariate 
(MV) generalized estimating equations were used. Factors included age, sex, marital 
status, disease duration, education level, number of major comorbidities, paid work 
status and 6-month baseline HAQ and RADAI levels. RESULTS: MV analyses 
revealed that the main predictors of HAQ were baseline HAQ: (OR: 0.49, 95% CI 
0.44, 0.54), number of comorbidities (1.09 (1.05, 1.14)), and age (1.02 (1.01, 1.02)); 
For RADAI they were, baseline RADAI (0.69 (0.66, 0.73)), comborbidities (1.11 
(1.07, 1.16)), and educational level (0.95 (0.93, 0.97)). CONCLUSIONS: Worse 
baseline levels of HAQ and RADAI predicted their respective improvement 6-months 
later. This could be due to optimization of treatment strategies when worse baseline 
scores are detected, but whatever the reason, performing these two patient reported 
outcomes are a quick and non-rheumatologist dependent way to improve patients’ 
disease status over 6-month intervals.
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OBJECTIVES: The demand for comparative effectiveness research (CER) data from 
payers, physicians, and patients is signiﬁ cant, but the cost and time associated with 
prospective randomized trials is a barrier to rapid decision-making. Use of patient-
reported outcomes (PROs) collected via on-line patient communities provides one 
channel for rapid data collection, particularly in conditions such as rheumatoid arthri-
tis (RA), where validated PRO instruments are available. METHODS: A random 
sample of iGuard.org members in the US treated with non-steroidal anti-inﬂ ammatory 
drug (NSAIDs), oral disease-modifying antirheumatic drugs (DMARDs), or biologics 
for RA completed the Rheumatoid Arthritis Disease Activity Index (RADAI) and a series 
of other questions related to their disease. iGuard.org is a free medication monitoring 
service that is introduced to patients through multiple sources including physician, 
pharmacy and online referrals. For this study, we report pilot baseline data on patient-
reported RADAI, pain, and joint counts across the three treatment groups to demon-
strate use of on-line communities in supporting CER. RESULTS: A total of 153 RA 
patients completed the study: 49 treated with NSAIDs only, 51 exposed to oral 
DMARDs, and 53 exposed to biologics. The mean (SD) RADAI score was 4.59 (2.16). 
Adjusting for age and gender and multiple comparisons, there were signiﬁ cant differ-
ences between the three treatment groups on RADAI scores (p = 0.0045) and patient 
global assessment of pain (p = 0.0357) but not on the number of painful joints (p = 
0.3512). The trend was towards patients on NSAIDs only having worse outcomes 
compared to patients on biologics or patients on oral DMARDs. CONCLUSIONS: 
This pilot study demonstrates the possibility of collecting baseline disease severity data 
directly from patients using the RADAI, which is sensitive to detect differences by 
treatment modality. The next step in the pilot program will be to investigate the 
potential for capturing longitudinal disease progress information amongst patients in 
on-line communities. 
RESPIRATORY-RELATED DISORDERS – Clinical Outcomes Studies
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OBJECTIVES: To examine the pattern of palivizumab utilization and compliance in 
infants with pre-existing disease within the Canadian Registry Database (CARESS). 
METHODS: A prospective, registry of infants across 27 sites who received at least 1 
dose of palivizumab during the 2006–2009 RSV seasons. Neonatal and demographic 
data were collected from the parent/caregiver at enrollment. Data on palivizumab 
utilization, compliance, and outcomes related to respiratory illness (RI) events were 
collected monthly. Premature infants ≤35 completed weeks gestational age without 
medical conditions who met standard approval criteria for palivizumab (Group 1) 
were compared to those with underlying medical disorders who received prophylaxis 
(Group 2). RESULTS: Group 1 (n = 3379) Group 2 (n = 489). Male: 56.8% versus 
54.6% (P = 0.433). Average Enrollment Age (months) ± SD: 3.6 ± 3.4 versus 9.9 ± 
8.8 (P = 0.000). Average GA (weeks) Mean ± SD: 31.0 ± 3.1 versus 37.1 ± 4.3 (P = 
0.000). Average # injections ± SD: 3.6 ± 1.5 versus 3.7 ± 1.5 (P = 0.159). Hospitaliza-
tion Rate (HR) for RI: 4.1% versus 9.2% (P = 0.000). RSV HR: 1.3% versus 2.7% 
(P < 0.05). On average infants received 86.0% ± 28.3% of the expected number of 
injections. Group 2 infants comprised Down syndrome (n = 118, 24.1%), upper 
airway anomalies (n = 112, 22.9%), cystic ﬁ brosis (n = 62, 12.7%), neuromuscular 
impairment (n = 42, 8.6%), pulmonary (n = 38, 7.8%), multiple system disorders (n 
= 34, 7.0%), cardiac (n = 17, 3.5%), immunocompromise (n = 8, 1.6%), and miscel-
laneous (n = 58, 11.9%). From 2006–2009, the proportion of Group 2 infants receiv-
ing prophylaxis increased 2-fold from 5.6% (69/1224) to12.2% (245/2016). Overall. 
Group 2 infants were older at enrollment with more advanced GA and had signiﬁ -
cantly higher RI and RSV hospitalization rates. No serious adverse events directly 
related to palivizumab occurred. CONCLUSIONS: Results imply that infants with 
underlying medical disorders that are not approved for prophylaxis by advisory bodies 
and current position statements are at greater risk for RSV infections and 
hospitalization.
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OBJECTIVES: Palivizumab is used for respiratory syncytial virus (RSV) prophylaxis 
in high risk children. Data on seasonality, risk factors, and outcomes are necessary to 
evaluate the impact of palivizumab on the incidence of RSV infections, minimize health 
care resources and identify which infant sub-sets are receiving prophylaxis.To deter-
mine current usage of palivizumab prophylaxis, compliance patterns, hospitalization 
rate (HR) and outcomes in children at high-risk of respiratory syncytial virus (RSV) 
infection through a Canadian Registry Database (CARESS). METHODS: A prospec-
tive, study of infants who received at least 1 dose of palivizumab in the 2006–2009 
RSV seasons across 27 sites. Neonatal and demographic data were collected upon 
enrolment. Parents/caregivers were contacted monthly for data on palivizumab utiliza-
tion, compliance and outcomes related to any respiratory tract events. RESULTS: A 
total of 4926 infants aged 2 days–47 months (mean = 5.4 months) were enrolled. 
Participants were typically male (57.1%) and Caucasian (70.8%). Gestational age 
(GA) was 32.2 ± 4.6 completed weeks. 3480 (70.6%) premature infants received 
palivizumab (≤35 completed weeks GA), 403 (8.2%) required O2, 471 (9.6%) had 
congenital heart disease and 572 (11.6%) were prophylaxed for other risk factors. On 
average patients received 3.7 ± 1.5 injections, with 17,982 doses given overall. There 
were no drug related serious adverse events.296 infants required 357 hospitalizations 
for respiratory tract infections with a hospitalization rate of 6.0%. There were signiﬁ -
cant differences between indications for palivizumab (chi-square = 71.8, P < 0.005).
The overall RSV positive HR was 1.38%. Hospitalization rates were highest in infants 
of aboriginal descent (15.0%, chi-square = 22.2, P < 0.005). Hospitalized infants had 
a lower percentage of compliant injections (62.8% versus 68.6%, p = 0.003). CON-
CLUSIONS: The RSV HR in the 2006–2009 RSV seasons resembled several published 
reports (range 1.3%–5.3%). RSV HR may be decreasing because of compliance with 
palivizumab prophylaxis, variability in RSV epidemiology, hospital admission criteria 
and preventive education.
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OBJECTIVES: Comorbidity is an important factor in any comparative assessment of 
treatments associated with morbidity and mortality of patients. Many factor such as 
age, gender and duration of a disease can inﬂ uence the impact of comorbid diseases 
on quality of life. In the health care setting (the primary source of data for most 
observational studies), the decision to give a particular treatment to a particular 
patient with a given disease is generally based on patient speciﬁ c characteristics, the 
most important of which is disease condition. Thus, confounding by indication/disease 
